Erratum: The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex (Nature Chemical Biology (2017) 13 (389-395) DOI: 10.1038/nchembio.2306);The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex

Nature Chemical Biology

Volumn 13, Issue 4, 2017, Pages 389-395

  He, Yupeng ^a   Selvaraju, Sujatha ^a   Curtin, Michael L ^a   Jakob, Clarissa G ^a   Zhu, Haizhong ^a   Comess, Kenneth M ^a   Shaw, Bailin ^a   The, Juliana ^b   Lima Fernandes, Evelyne ^b,c   Szewczyk, Magdalena M ^b   Cheng, Dong ^a   Klinge, Kelly L ^a   Li, Huan Qiu ^a   Pliushchev, Marina ^a   Algire, Mikkel A ^a   Maag, David ^a   Guo, Jun ^a   Dietrich, Justin ^a   Panchal, Sanjay C ^a   Petros, Andrew M ^a   Sweis, Ramzi F ^a   Torrent, Maricel ^a   Bigelow, Lance J ^a   Senisterra, Guillermo ^b   Li, Fengling ^b   Kennedy, Steven ^b   Wu, Qin ^b,c   Osterling, Donald J ^a   Lindley, David J ^a   Gao, Wenqing ^a   Galasinski, Scott ^a   Barsyte Lovejoy, Dalia ^b   Vedadi, Masoud ^b   Buchanan, Fritz G ^a   Arrowsmith, Cheryl H ^b,c   Chiang, Gary G ^a,d   Sun, Chaohong ^a   Pappano, William N ^a   more..

^a ABBVIE INC   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d FFECTOR Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 395; EMBRYONIC ECTODERM DEVELOPMENT PROTEIN; HISTONE H3; LYSINE; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; A-395 COMPOUND; ANTINEOPLASTIC AGENT; EED PROTEIN, HUMAN; INDAN DERIVATIVE; PROTEIN BINDING; SULFONAMIDE;

ALLOSTERISM; ARTICLE; CATALYSIS; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HUMAN; METABOLISM; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 85010929512     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio0817-922b     Document Type: Erratum

References (56)

1. Lewis, E.B. A gene complex controlling segmentation in Drosophila. Nature 276, 565-570 (1978).
2. Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343-349 (2011).
3. Simon, J.A. & Kingston, R.E. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat. Rev. Mol. Cell Biol. 10, 697-708 (2009).
4. Levine, S.S. et al. The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans. Mol. Cell. Biol. 22, 6070-6078 (2002).
5. Cao, R., Tsukada, Y. & Zhang, Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol. Cell 20, 845-854 (2005).
6. Wang, H. et al. Role of histone H2A ubiquitination in Polycomb silencing. Nature 431, 873-878 (2004).
7. Cao, R. et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298, 1039-1043 (2002).
8. Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P. & Reinberg, D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 16, 2893-2905 (2002).
9. Di Croce, L. & Helin, K. Transcriptional regulation by Polycomb group proteins. Nat. Struct. Mol. Biol. 20, 1147-1155 (2013).
10. Margueron, R. et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol. Cell 32, 503-518 (2008).
11. Shen, X. et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol. Cell 32, 491-502 (2008).
12. Hansen, K.H. et al. A model for transmission of the H3K27me3 epigenetic mark. Nat. Cell Biol. 10, 1291-1300 (2008).
13. Margueron, R. et al. Role of the polycomb protein EED in the propagation of repressive histone marks. Nature 461, 762-767 (2009).
14. Xu, C. et al. Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2). Proc. Natl. Acad. Sci. USA 107, 19266-19271 (2010).
15. Jiao, L. & Liu, X. Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2. Science 350, aac4383 (2015).
16. Justin, N. et al. Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2. Nat. Commun. 7, 11316 (2016).
17. Brooun, A. et al. Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance. Nat. Commun. 7, 11384 (2016).
18. Faust, C., Schumacher, A., Holdener, B. & Magnuson, T. The eed mutation disrupts anterior mesoderm production in mice. Development 121, 273-285 (1995).
19. O'Carroll, D. et al. The polycomb-group gene Ezh2 is required for early mouse development. Mol. Cell. Biol. 21, 4330-4336 (2001).
20. Pasini, D., Bracken, A.P., Hansen, J.B., Capillo, M. & Helin, K. The polycomb group protein Suz12 is required for embryonic stem cell differentiation. Mol. Cell. Biol. 27, 3769-3779 (2007).
21. McCabe, M.T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112 (2012).
22. Morin, R.D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181-185 (2010).
23. Morin, R.D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298-303 (2011).
24. Pasqualucci, L. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 43, 830-837 (2011).
25. Ryan, R.J. et al. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS One 6, e28585 (2011).
26. Sneeringer, C.J. et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl. Acad. Sci. USA 107, 20980-20985 (2010).
27. Chan, K.M. et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 27, 985-990 (2013).
28. Lewis, P.W. et al. Inhibition of PRC2 activity by a gain-of-function H3 H3 mutation found in pediatric glioblastoma. Science 340, 857-861 (2013).
29. Garapaty-Rao, S. et al. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem. Biol. 20, 1329-1339 (2013).
30. Konze, K.D. et al. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8, 1324-1334 (2013).
31. Knutson, S.K. et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8, 890-896 (2012).
32. Lo, M.C. et al. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal. Biochem. 332, 153-159 (2004).
33. Pantoliano, M.W. et al. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J. Biomol. Screen. 6, 429-440 (2001).
34. Senisterra, G., Chau, I. & Vedadi, M. Thermal denaturation assays in chemical biology. Assay Drug Dev. Technol. 10, 128-136 (2012).
35. Couture, J.F., Collazo, E. & Trievel, R.C. Molecular recognition of histone H3 by the WD40 protein WDR5. Nat. Struct. Mol. Biol. 13, 698-703 (2006).
36. Schwartz, Y.B. & Pirrotta, V. A new world of Polycombs: unexpected partnerships and emerging functions. Nat. Rev. Genet. 14, 853-864 (2013).
37. Krissinel, E. & Henrick, K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr. D Biol. Crystallogr. 60, 2256-2268 (2004).
38. Camerino, M.A. et al. The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface. MedChemComm 4, 1501-1507 (2013).
39. McCabe, M.T. et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl. Acad. Sci. USA 109, 2989-2994 (2012).
40. Hernando, H. et al. EZH2 inhibition blocks multiple myeloma cell growth through upregulation of epithelial tumor suppressor genes. Mol. Cancer Ther. 15, 287-298 (2016).
41. Knutson, S.K. et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl. Acad. Sci. USA 110, 7922-7927 (2013).
42. Baker, T. et al. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors. Oncotarget 6, 32646-32655 (2015).
43. Gibaja, V. et al. Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors. Oncogene 35, 558-566 (2016).
44. Sadikovic, B., Al-Romaih, K., Squire, J.A. & Zielenska, M. Cause and consequences of genetic and epigenetic alterations in human cancer. Curr. Genomics 9, 394-408 (2008).
45. Arrowsmith, C.H., Bountra, C., Fish, P.V., Lee, K. & Schapira, M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11, 384-400 (2012).
46. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010).
47. Ueda, T. et al. EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms. Leukemia 26, 2557-2560 (2012).
48. Fresquet, V., Rieger, M., Carolis, C., Garcia-Barchino, M.J. & Martinez-Climent, J.A. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood 123, 4111-4119 (2014).
49. Barsyte-Lovejoy, D. et al. (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells. Proc. Natl. Acad. Sci. USA 111, 12853-12858 (2014).
50. Kaustov, L. et al. Recognition and specificity determinants of the human cbx chromodomains. J. Biol. Chem. 286, 521-529 (2011).
51. Niesen, F.H., Berglund, H. & Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2, 2212-2221 (2007).
52. Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D Biol. Crystallogr. 67, 293-302 (2011).
53. McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
54. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
55. Murshudov, G.N., Vagin, A.A. & Dodson, E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997).
56. Pappano, W.N. et al. The histone methyltransferase inhibitor A-366 uncovers a role for G9a/GLP in the epigenetics of leukemia. PLoS One 10, e0131716 (2015).